Oxytocin for Hypermobile Ehlers-Danlos Syndrome (EDS-OXY)
Oxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos Syndrome
Sponsor: Baylor College of Medicine
Terminated
Study team has decided to close the trial (NCT05405257) due problems with patient recruitment and enrollment efforts. To date, only one patient completed both arms.
A PHASE1/PHASE2 clinical study on Hypermobile Ehlers-Danlos Syndrome and Pain Assessment, this trial is terminated or withdrawn. The trial is conducted by Baylor College of Medicine and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 1 earlier version
-
Jul 2022 — Jun 2023 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .